Copyright
©2013 Baishideng Publishing Group Co.
World J Gastrointest Endosc. Apr 16, 2013; 5(4): 180-185
Published online Apr 16, 2013. doi: 10.4253/wjge.v5.i4.180
Published online Apr 16, 2013. doi: 10.4253/wjge.v5.i4.180
Yes | No | Our patient | |
1: Are there previous conclusive reports on this reaction? | 1 | 0 | 0 |
2: Did the adverse event appear after the suspected drug was administered? | 2 | -1 | 2 |
3: Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? | 1 | 0 | 1 |
4: Did the adverse reaction reappear when the drug was readministered? | 2 | -1 | 0 |
5: Are there alternative causes (other than the drug) that could have, on their own, caused the reaction? | -1 | 2 | 2 |
6: Did the reaction appear when a placebo was given? | -1 | 1 | 1 |
7: Was the drug detected in the blood (or other fluids) in concentration known to be toxic? | 1 | 0 | 0 |
8: Was the reaction more severe when the dose was increased or less severe when dose was decreased? | 1 | 0 | 0 |
9: Did the patient have a similar reaction to the same or similar drugs in any previous exposure? | 1 | 0 | 0 |
10: Was the adverse event confirmed by any objective evidence? | 1 | 0 | 1 |
- Citation: Sherid M, Samo S, Sulaiman S, Gaziano JH. Ischemic colitis induced by the newly reformulated multicomponent weight-loss supplement Hydroxycut®. World J Gastrointest Endosc 2013; 5(4): 180-185
- URL: https://www.wjgnet.com/1948-5190/full/v5/i4/180.htm
- DOI: https://dx.doi.org/10.4253/wjge.v5.i4.180